Imbrium Therapeutics
June 16, 2025
Company Presentation
Multiple Therapeutics
Imbrium Therapeutics is a privately held clinical stage biopharmaceutical company dedicated to advancing medical science by developing new non-opioid therapies to treat pain, cancer, genitourinary disorders, and disorders of the central nervous system.
Imbrium Therapeutics is pursuing non-opioid approaches to pain management, as well as treatments for genitourinary disorders, disorders of the central nervous system, and cancer. Imbrium strives to develop new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. We have built a diversified pipeline of investigational drug candidates, and we seek to actively collaborate with industry and academic partners to identify and advance future impactful medicines. As a wholly owned subsidiary of Purdue Pharma L.P., Imbrium has access to full range of business capabilities.
Company HQ City:
Stamford
Company HQ State:
CT
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
Sunibinop, a novel nociceptin partial agonist in development for insomnia, alcohol use disorder, overactive bladder, and interstitial cystitis
CEO
Craig Landau
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
Two
When you expect your next catalyst update?
Completion of Phase 1b/2a interstitial cystitis trial
What is your next catalyst (value inflection) update?
April, 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}